Home » Stocks » KRON

Kronos Bio, Inc. (KRON)

Stock Price: $25.69 USD 0.20 (0.78%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $24.00 -1.69 (-6.58%) May 7, 5:21 PM
Market Cap 1.51B
Revenue (ttm) n/a
Net Income (ttm) -88.44M
Shares Out 56.07M
EPS (ttm) -5.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $25.69
Previous Close $25.49
Change ($) 0.20
Change (%) 0.78%
Day's Open 25.62
Day's Range 24.92 - 26.78
Day's Volume 107,860
52-Week Range 19.60 - 39.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

3 weeks ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the...

1 month ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the...

1 month ago - GlobeNewsWire

Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia

1 month ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

1 month ago - GlobeNewsWire

Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval

2 months ago - GlobeNewsWire

KB-0742 generated using the company's proprietary small molecule microarray (SMM) screening platform

2 months ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced part...

2 months ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the ...

3 months ago - GlobeNewsWire

MYC amplification found in approximately 30% of solid tumors

5 months ago - GlobeNewsWire

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

5 months ago - GlobeNewsWire

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia

5 months ago - GlobeNewsWire

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

5 months ago - GlobeNewsWire

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, SPRB, STTK
6 months ago - Seeking Alpha

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CCL, BAM, FUBO, HEI, STTK
6 months ago - Benzinga

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel ...

6 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, MAACU, MUDSU, NGACU, SPRB, STTK
6 months ago - Seeking Alpha

Shares of Kronos Bio Inc. soared in their public debut, as they opened 50% above the initial public offering price. The stock's first trade was at $28.50 at 11:58 a.m.

6 months ago - Market Watch

This week has down with 6 IPOS scheduled for Thursday and Friday. FuboTV: Sport first live tv streaming company Fubo TV (OTC: FUBO) is uplisting to the Nasdaq.

Other stocks mentioned: FUBO
6 months ago - Benzinga

Kronos Bio Inc. priced its upsized initial public offering at $19 a share, above its $16 to $18 price range. The California-based biotech sold 13.2 million shares to raise about $250.8 million.

6 months ago - Market Watch

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeu...

6 months ago - GlobeNewsWire

Kronos Bio Inc. KRON, disclosed Thursday that its initial public offering was upsized by about 28%, as the California-based biopharmaceutical now looks to raise up to $236.8 million

6 months ago - Market Watch

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy... [Read more...]

Industry
Pharmaceutical Preparation Manufacturing
IPO Date
Oct 9, 2020
Stock Exchange
NASDAQ
Ticker Symbol
KRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Kronos Bio stock is "Buy." The 12-month stock price forecast is 44.33, which is an increase of 72.56% from the latest price.

Price Target
$44.33
(72.56% upside)
Analyst Consensus: Buy